Fortunately, the advent of novel BCR inhibitors has indirectly provided first clues for a better understanding of the mechanisms through which CCR7 creates and preserves protective and tolerogenic milieus, prolongs CLL cell residency in these niches (contributing, therefore, to lymphadenopathy), and provides escape from therapeutic agents. This evidence concerns the gene BCR and B-cell chronic lymphocytic leukemia.